Table 2 Clinicopathologic correlation of tumour microenvironment immune types, CD8 expression, and PD-L1 expression
Parameters | Tumour microenvironment immune type (%) | CD8 expression (%) | PD-L1 expression (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ā | Type I(PDL1+/CD8H) | Type IV(PD-L1ā/CD8H) | Type III(PD-L1+/ CD8L) | Type II (PD-L1ā/CD8L) | P | Low | High | P | Neg. | Pos. | P | ||
Age | Less than 67āyrs | 36 (17.4) | 36 (17.4) | 35 (16.9) | 100 (48.3) | 0.366 | 135 (65.2) | 72 (34.8) | 0.575 | 136 (65.4) | 72 (35.6) | 0.303 | |
More than 67āyrs | 54 (19.9) | 47 (17.3) | 52 (19.2) | 118 (43.5) | Ā | 170 (62.7) | 101 (37.3) | Ā | 166 (60.8) | 107 (39.2) | Ā | ||
Sex | Male | 58 (20.3) | 57 (19.9) | 46 (16.1) | 125 (43.7) | 0.094 | 171 (59.8) | 115 (40.2) | 0.026* | 182 (63.2) | 106 (36.8) | 0.821 | |
Female | 32 (16.7) | 26 (13.5) | 41 (21.4) | 93 (48.4) | Ā | 134 (69.8) | 58 (30.2) | Ā | 120 (62.2) | 73 (37.8) | Ā | ||
Size | Less than 4.9ācm | 50 (20.0) | 48 (19.2) | 43 (17.2) | 109(43.6) | 0.227 | 152 (60.8) | 98 (39.2) | 0.15āl2 | 157 (62.5) | 94 (37.5) | 0.911 | |
More than 4.9ācm | 40 (17.5) | 35 (15.4) | 44 (19.3) | 109 (47.8) | Ā | 153 (67.1) | 75 (32.9) | Ā | 145 (63.0) | 85 (37.0) | Ā | ||
Location | Ascending | 26 (24.3) | 18 (16.8) | 22 (20.6) | 41 (38.3) | 0.912 | 63 (58.9) | 44 (41.1) | 0.849 | 59 (54.6) | 49 (45.4) | 0.517 | |
Transverse to sigmoid | 34 (14.2) | 41 (17.2) | 42 (17.6) | 122 (51.0) | Ā | 164 (68.6) | 75 (31.4) | Ā | 164 (68.3) | 76 (31.7) | Ā | ||
Rectum | 27 (23.1) | 22 (18.8) | 20 (17.1) | 48 (41.0) | Ā | 68 (58.1) | 49 (41.9) | Ā | 70 (59.3) | 48 (40.7) | Ā | ||
Histologic type | Intestinal type | 89 (18.9) | 83 (17.7) | 87 (18.5) | 211 (44.9) | 0.080 | 298 (63.4) | 172 (36.6) | 0.160 | 295 (62.4) | 178 (37.6) | 0.145 | |
Mucinous type | 1 (12.5) | 0 (0.0) | 0 (0.0) | 7 (87.5) | Ā | 7 (87.5) | 1 (12.5) | Ā | 7 (87.5) | 1 (12.5) | Ā | ||
Differentiation | Well | 9 (17.6) | 14 (27.5) | 8 (15.7) | 20 (39.2) | 0.795 | 28 (54.9) | 23 (45.1) | 0.458 | 34 (65.4) | 18 (34.60 | 0.483 | |
Moderately | 75 (18.7) | 66 (16.5) | 76 (19.0) | 184 (45.7) | Ā | 260 (64.8) | 141 (35.2) | Ā | 251 (62.3) | 152 (37.7) | Ā | ||
Poorly | 5 (27.8) | 3 (16.7) | 3 (16.7) | 7 (38.9) | Ā | 10 (55.6) | 8 (44.4) | Ā | 10 (55.6) | 8 (44.4) | Ā | ||
Lymphovascular invasion | Absence | 65 (20.4) | 47 (14.8) | 58 (18.2) | 148 (46.5) | 0.955 | 206 (64.8) | 112 (35.2) | 0.503 | 196 (61.1) | 125 (38.9) | 0.211 | |
Presence | 21 (14.7) | 34 (23.8) | 26 (18.2) | 62 (43.4) | Ā | 88 (61.5) | 55 (38.5) | Ā | 96 (67.1) | 47 (32.9) | Ā | ||
Perineural invasion | Absence | 58 (19.7) | 43 (14.6) | 59 (20.0) | 135 (45.8) | 0.650 | 194 (65.8) | 101 (34.2) | 0.808 | 178 (60.3) | 117 (39.7) | 0.116 | |
Presence | 7 (14.0) | 11 (22.0) | 7 (14.0) | 25 (50.0) | Ā | 32 (64.0) | 18 (36.0) | Ā | 36 (72.0) | 14 (28.0) | Ā | ||
pT category | pT1ā2 | 26 (32.9) | 17 (21.5) | 15 (19.0) | 21(26.6) | <ā 0.001* | 36 (45.6) | 43 (54.4) | 0.001* | 178 (60.3) | 117 (39.7) | 0.001* | |
pT3 | 58 (16.8) | 56 (16.2) | 65 (18.8) | 166(48.0) | Ā | 231 (67.0) | 114 (33.0) | Ā | 36 (72.0) | 14 (28.0) | Ā | ||
pT4 | 6 (11.1) | 10 (18.5) | 7 (13.0) | 31 (57.4) | Ā | 38 (70.4) | 16 (29.6) | Ā | 178 (60.3) | 117 (39.7) | Ā | ||
Lymph node metastasis | Absence | 68 (25.3) | 43 (16.0) | 47 (17.5) | 111 (41.3) | 0.001* | 158 (58.7) | 111(41.3) | 0.009* | 154 (56.8) | 117 (43.2) | 0.002* | |
Presence | 22 (10.5) | 40 (19.1) | 40 (19.1) | 107 (51.2) | Ā | 147 (70.3) | 62 (29.3) | Ā | 148 (70.5) | 62 (29.5) | Ā | ||
Stage | I | 24 (37.5) | 11 (17.2) | 11 (17.2) | 18 (28.1) | 0.001* | 29 (45.3) | 35 (54.7) | 0.006* | 29 (45.3) | 35 (54.7) | 0.003* | |
II | 41 (20.5) | 30 (15.0) | 34 (17.0) | 95 (47.5) | Ā | 129 (64.5) | 71 (35.5) | Ā | 125 (61.9) | 77 (38.1) | Ā | ||
III | 21 (10.9) | 38 (19.6) | 38 (19.8) | 95(19.5) | Ā | 133 (69.3) | 59(30.7) | Ā | 134 (69.4) | 59 (30.6) | Ā | ||
IV | 4 (18.2) | 4 (18.2) | 4 (18.2) | 10 (45.5) | Ā | 14 (63.6) | 8 (36.4) | Ā | 14 (63.6) | 8 (36.4) | Ā | ||
Deficient mismatch repair | Absence | 76 (17.3) | 76 (17.3) | 81 (18.5) | 206 (46.9) | 0.006* | 287 (65.4) | 152 (34.6) | 0.017* | 283 (64.2) | 158 (35.8) | 0.037* | |
Presence | 14 (35.9) | 7 (17.9) | 6 (15.4) | 12 (30.8) | Ā | 18 (46.2) | 21 (53.8) | Ā | 19 (47.5) | 21 (52.5) | Ā | ||
Neoadjuvant chemoradiotherapy | Absent | 88 (18.2) | 77 (16.5) | 86 (18.5) | 215 (46.1) | 0.025* | 301 (64.6) | 165 (35.4) | 0.026* | 293 (62.5) | 176 (37.5) | 0.375 | |
Present | 2 (16.7) | 6 (50.0) | 1 (8.3) | 3 (25.0) | Ā | 4 (33.3) | 8 (66.7) | Ā | 9 (75.0) | 3 (25.0) | Ā | ||
Local recurrence | Absence | 67 (22.3) | 51 (17.0) | 52 17.3) | 130 (43.3) | 0.031* | 182 (60.7) | 118 (39.3) | 0.064 | 181 (59.9) | 121 (40.1) | 0.093 | |
Presence | 23 (12.9) | 32 (18.0) | 35 (19.7) | 88 (49.4) | Ā | 123 (69.1) | 55 (30.9) | Ā | 121 (67.6) | 58 (32.4) | Ā | ||
Disease-specific death | Alive | 69 (24.0) | 49 (17.1) | 48 (16.7) | 121 (42.2) | 0.002* | 169 (58.9) | 118 (41.1) | 0.006* | 170 (58.8) | 119 (41.2) | 0.027* | |
Dead | 21 (11.0) | 34 (17.8) | 39 (20.4) | 97 (50.8) | Ā | 136 (71.2) | 55 (28.8) | Ā | 132 (68.8) | 60 (31.3) | Ā | ||